Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.

Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Miller M, Tardif JC, Ketchum SB, Doyle RT Jr, Murphy SA, Soni PN, Braeckman RA, Juliano RA, Ballantyne CM; REDUCE-IT Investigators.

Clin Cardiol. 2017 Mar;40(3):138-148. doi: 10.1002/clc.22692. Epub 2017 Mar 15.

2.

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.

Ballantyne CM, Bays HE, Philip S, Doyle RT Jr, Braeckman RA, Stirtan WG, Soni PN, Juliano RA.

Atherosclerosis. 2016 Oct;253:81-87. doi: 10.1016/j.atherosclerosis.2016.08.005. Epub 2016 Aug 20.

3.

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.

Ballantyne CM, Bays HE, Braeckman RA, Philip S, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA.

J Clin Lipidol. 2016 May-Jun;10(3):635-645.e1. doi: 10.1016/j.jacl.2016.02.008. Epub 2016 Feb 23.

4.

Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetic Parameters of Rosiglitazone in Healthy Subjects.

Braeckman RA, Stirtan WG, Soni PN.

Clin Pharmacol Drug Dev. 2015 Mar;4(2):143-148. Epub 2014 Dec 3.

5.

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study).

Ballantyne CM, Braeckman RA, Bays HE, Kastelein JJ, Otvos JD, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA.

J Clin Lipidol. 2015 May-Jun;9(3):377-83. doi: 10.1016/j.jacl.2014.11.009. Epub 2014 Nov 29.

6.

Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome.

Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Doyle RT Jr, Philip S, Soni PN, Juliano RA.

Metab Syndr Relat Disord. 2015 Aug;13(6):239-47. doi: 10.1089/met.2014.0137. Epub 2015 Apr 20.

PMID:
25893544
7.

Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin.

Braeckman RA, Stirtan WG, Soni PN.

Clin Drug Investig. 2015 Jan;35(1):45-51. doi: 10.1007/s40261-014-0252-8.

8.

Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults.

Braeckman RA, Stirtan WG, Soni PN.

Drugs R D. 2014 Sep;14(3):159-64. doi: 10.1007/s40268-014-0053-9.

9.

Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters.

Braeckman RA, Stirtan WG, Soni PN.

Clin Drug Investig. 2014 Jul;34(7):449-56. doi: 10.1007/s40261-014-0194-1.

PMID:
24760401
10.

Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects.

Braeckman RA, Stirtan WG, Soni PN.

Clin Pharmacol Drug Dev. 2014 Mar;3(2):101-108. Epub 2013 Oct 22.

11.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).

Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN.

Prostaglandins Leukot Essent Fatty Acids. 2013 Sep;89(4):195-201. doi: 10.1016/j.plefa.2013.07.005. Epub 2013 Aug 1.

PMID:
23992935
12.

Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.

Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN.

Cardiovasc Diabetol. 2013 Jul 9;12:100. doi: 10.1186/1475-2840-12-100. Erratum in: Cardiovasc Diabetol. 2015 Jul-Aug;9(4):618.

13.

Icosapent ethyl for the treatment of hypertriglyceridemia.

Ballantyne CM, Braeckman RA, Soni PN.

Expert Opin Pharmacother. 2013 Jul;14(10):1409-16. doi: 10.1517/14656566.2013.798645. Epub 2013 May 24.

PMID:
23701295
14.

Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.

Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN.

Am J Cardiovasc Drugs. 2013 Feb;13(1):37-46. doi: 10.1007/s40256-012-0002-3.

15.

Authors' reply.

Ballantyne CM, Bays HE, Braeckman RA, Soni PN.

Am J Cardiol. 2013 Feb 1;111(3):455-6. doi: 10.1016/j.amjcard.2012.11.036. No abstract available.

PMID:
23317532
16.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).

Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN.

J Clin Lipidol. 2012 Nov-Dec;6(6):565-72. doi: 10.1016/j.jacl.2012.07.001. Epub 2012 Jul 24.

PMID:
23312052
17.

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20.

PMID:
22819432
18.

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2011 Sep 1;108(5):682-90. doi: 10.1016/j.amjcard.2011.04.015. Epub 2011 Jun 16.

PMID:
21683321
19.

PX3.102, a novel chinese herb extract, diminishes chronic airway allograft rejection.

Chalermskulrat W, Neuringer IP, Park RC, Brickey WJ, Braeckman RA, Randell SH, Aris RM.

Transplantation. 2004 Jul 15;78(1):158-61.

PMID:
15257056
20.

The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor.

Kemme MJ, Burggraaf J, Schoemaker RC, Paulson S, Karim A, Lentjes EG, Childs A, Braeckman RA, Cohen AF.

Clin Pharmacol Ther. 2000 May;67(5):504-11.

PMID:
10824629
21.

Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs.

Chen SA, Sawchuk RJ, Brundage RC, Horvath C, Mendenhall HV, Gunther RA, Braeckman RA.

J Pharmacol Exp Ther. 2000 Apr;293(1):248-59.

22.

Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution.

Laham RJ, Rezaee M, Post M, Sellke FW, Braeckman RA, Hung D, Simons M.

Drug Metab Dispos. 1999 Jul;27(7):821-6.

23.

Practical aspects of assessing toxicokinetics and toxicodynamics.

Johnson DE, Braeckman RA, Wolfgang GH.

Curr Opin Drug Discov Devel. 1999 Jan;2(1):49-57.

PMID:
19649917
24.

Intestinal absorption screening of mixtures from combinatorial libraries in the Caco-2 model.

Taylor EW, Gibbons JA, Braeckman RA.

Pharm Res. 1997 May;14(5):572-7.

PMID:
9165526
25.

Pharmacologic characterization of CHIR 2279, an N-substituted glycine peptoid with high-affinity binding for alpha 1-adrenoceptors.

Gibbons JA, Hancock AA, Vitt CR, Knepper S, Buckner SA, Brune ME, Milicic I, Kerwin JF Jr, Richter LS, Taylor EW, Spear KL, Zuckermann RN, Spellmeyer DC, Braeckman RA, Moos WH.

J Pharmacol Exp Ther. 1996 May;277(2):885-99.

PMID:
8627571
26.

The effect of zileuton on antipyrine and indocyanine green disposition.

St Peter JV, Braeckman RA, Granneman GR, Locke CS, Cavanaugh JH, Awni WM.

Clin Pharmacol Ther. 1995 Mar;57(3):299-308.

PMID:
7697947
27.
28.

Effect of zileuton on theophylline pharmacokinetics.

Granneman GR, Braeckman RA, Locke CS, Cavanaugh JH, Dubé LM, Awni WM.

Clin Pharmacokinet. 1995;29 Suppl 2:77-83.

PMID:
8620674
29.

The effect of mild or moderate hepatic impairment (cirrhosis) on the pharmacokinetics of zileuton.

Awni WM, Cavanaugh JH, Braeckman RA, Chu SY, Patterson KJ, Machinist JM, Granneman GR.

Clin Pharmacokinet. 1995;29 Suppl 2:49-61.

PMID:
8620671
30.

The pharmacokinetics of zileuton in healthy young and elderly volunteers.

Braeckman RA, Granneman GR, Locke CS, Machinist JM, Cavannaugh JH, Awni WM.

Clin Pharmacokinet. 1995;29 Suppl 2:42-8.

PMID:
8620670
31.
32.

The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.

Awni WM, Braeckman RA, Cavanaugh JH, Locke CS, Linnen PJ, Granneman GR, Dubé LM.

Clin Pharmacokinet. 1995;29 Suppl 2:112-24.

PMID:
8620667
33.
34.

Quantitation of the renal clearance of interleukin-2 using nephrectomized and ureter-ligated rats.

Gibbons JA, Luo ZP, Hannon ER, Braeckman RA, Young JD.

J Pharmacol Exp Ther. 1995 Jan;272(1):119-25.

PMID:
7815324
35.

Pharmacokinetics of 8-methoxypsoralen in the dog.

Monbaliu JG, Belpaire FM, Braeckman RA, Bogaert MG.

Biopharm Drug Dispos. 1988 Jan-Feb;9(1):9-17.

PMID:
3342288
36.

Binding of oxprenolol and propranolol to serum, albumin and alpha 1-acid glycoprotein in man and other species.

Belpaire FM, Braeckman RA, Bogaert MG.

Biochem Pharmacol. 1984 Jul 1;33(13):2065-9.

PMID:
6743355
37.

Toxicokinetics of methyl parathion and parathion in the dog after intravenous and oral administration.

Braeckman RA, Audenaert F, Willems JL, Belpaire FM, Bogaert MG.

Arch Toxicol. 1983 Sep;54(1):71-82.

PMID:
6639354
38.

Combined hemoperfusion-hemodialysis in organophosphate poisoning.

Nagler J, Braeckman RA, Willems JL, Verpooten GA, De Broe ME.

J Appl Toxicol. 1981 Aug;1(4):199-201.

PMID:
7184937
39.

Kinetic analysis of the fate of methyl parathion in the dog.

Braeckman RA, Godefroot MG, Blondeel GM, Belpaire FM, Willems JL.

Arch Toxicol. 1980 Feb;43(4):263-71.

PMID:
7387386
40.

Pharmacokinetics of bromhexine in the dog.

Vandecasteele-Thienpont LM, Belpaire FM, Braeckman RA, De Leenheer AP.

Arzneimittelforschung. 1980;30(10):1643-5.

PMID:
7192102

Supplemental Content

Loading ...
Support Center